VEGF Receptor 2 Antibody (YA014)

製品番号: HY-P80370: データシート SDS COA User Guide for Antibodies
FAQs
Technical Support

VEGF Receptor 2 Antibody (YA014) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VEGF Receptor 2.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

容量	価格（税別）	在庫状況	数量
20 μL	$126	在庫あり	Estimated Time of Arrival: December 31
50 μL	$185	在庫あり	Estimated Time of Arrival: December 31
100 μL	$300	在庫あり	Estimated Time of Arrival: December 31
250 μL		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

おすすめ:

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Verification Image
Background
説明

製品説明

VEGF Receptor 2 Antibody (YA014) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VEGF Receptor 2.

Host

Rabbit

Clonality

Recombinant,Monoclonal

分子量

Predicted band size: 150 kDa;

Observed band size: 150/250 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human, Rat

SwissProt ID

P35968

Gene ID

3791 [NCBI]

Immunogen

Synthetic peptide corresponding to Human VEGF Receptor 2.AA range:30-630.

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:500-1:1000
ICC/IF ICC/IF: Immunocytochemistry/Immunofluorescence	1:50-1:200
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:50-1:100
IP IP: Immunoprecipitation	Use at an assay dependent concentration.

Sensitivity	Endogenous	純度	Protein A affinity purified.
Conjugation	Non-conjugated	Modification	Unmodified
Isotype	IgG

Appearance

Liquid

Formulation

Supplied in 1*TBS (pH7.4), 0.05% BSA and 40% Glycerol. Preservative: 0.05% Sodium Azide.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

輸送条件

Shipping with blue ice.

Verification Image

IHC-P

Immunohistochemical analysis of paraffin-embedded human Kidney cancer tissue using VEGF Receptor 2 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P80370, 1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.
Immunohistochemical analysis of paraffin-embedded human Liver tissue using VEGF Receptor 2 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P80370, 1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.
Immunohistochemical analysis of paraffin-embedded human Liver Cancer tissue using VEGF Receptor 2 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P80370, 1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.
Immunohistochemical analysis of paraffin-embedded human Liver Cancer tissue using VEGF Receptor 2 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P80370, 1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.
Immunohistochemical analysis of paraffin-embedded human Liver Cancer tissue using VEGF Receptor 2 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P80370, 1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.
Immunohistochemical analysis of paraffin-embedded human Endometrial Carcinoma tissue using VEGF Receptor 2 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P80370, 1:100 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.

Background

Function：Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC

Subcellular Localization：Cell junction; Endoplasmic reticulum; Cell membrane; Cell membrane; Single-pass type I membrane protein; Cytoplasm; Nucleus; Cytoplasmic vesicle; Early endosome; Secreted; Secreted

Expression：
Tissue_specificity:Detected in the cornea (protein level) . Widely expressed.

Subunit：Homodimer in the presence of bound dimeric VEGFA, VEGFC or VEGFD ligands; monomeric in the absence of bound ligands. Can also form heterodimers with FLT1/VEGFR1 and KDR/VEGFR2. Interacts (tyrosine phosphorylated) with LFYN, NCK1, PLCG1. Interacts (tyrosine-phosphorylated active form preferentially) with DAB2IP (via C2 domain and active form preferentially); the interaction occurs at the late phase of VEGFA response and inhibits KDR/VEGFR2 activity. Interacts with SHBSH2D2A/TSAD, GRB2, MYOF, CBL and PDCD6. Interacts (via C-terminus domain) with ERN1 (via kinase domain); the interaction is facilitated in a XBP1 isoform 1- and vascular endothelial growth factor (VEGF)-dependent manner in endothelial cells (PubMed:23529610). Interacts (via juxtamembrane region) with chaperone PDCL3 (via thioredoxin fold region); the interaction leads to increased KDR/VEGFR2 abundance through inhibition of its ubiquitination and degradation (PubMed:23792958, PubMed:26059764). Interacts (tyrosine phosphorylated) with CCDC88A/GIV (via SH2-like region); binding requires autophosphorylation of the KDR/VEGFR2 C-terminal region (PubMed:25187647). Interacts with isoform 2 of BSG (PubMed:25825981). Interacts with SLC31A1; this interaction is induced upon VEGFA stimulation leading to SLC31A1 and KDR subsequent co-internalization to early endosomes, thereby activating KDR downstream signaling in endothelial cells (PubMed:35027734)

RRID

AB_3102460

Database

Entrez Gene: 3791 Human ; 25589 Rat

SwissProt: P35968 Human ; O08775 Rat

OMIM: 602089 Human

Research Field

Epigenetics and Nuclear Signaling

Synonyms

VEGFR-2; FLK-1; KDR

ドキュメンテーション

Select Batch:

データシート (235 KB) SDS (252 KB)

COA (206 KB)

User Guide for Antibodies (1077 KB)